Skip to content
Search AI Powered

Latest Stories

What’s Going on with New York’s Legal Cannabis Roll Out? 

What's Going on With New York's Legal Cannabis Rollout
What's Going on With New York's Legal Cannabis Rollout

The New York cannabis industry is facing a complex and challenging landscape as it transitions from a medical marijuana program to a fully legal recreational market. Despite the recent legalization of adult-use cannabis in the state, there are still many issues to be addressed, including regulatory compliance, licensing, distribution, capital and equity concerns, and of course, litigation.

Recently, several lawsuits have been filed against the New York State Cannabis Control Board (CCB) and the Office of Cannabis Management (OCM), which are the agencies responsible for overseeing the state's cannabis industry.


One of the lawsuits filed in late in 2022, was brought forth by Variscite, a company registered under the laws of New York, which applied for a CAURD (Cannabis Control Board Adult-Use Retail Dispensary) license. At issue is the fact that the majority owner of Variscite had a cannabis conviction under Michigan law and no significant connection to New York, Variscite was deemed ineligible for the license. 

Variscite argued in its lawsuit that the New York residency requirement was discriminatory against out-of-state applicants and violated the Dormant Commerce Clause (DCC) implied in the Constitution. A federal judge agreed with Variscite's argument and ruled that the residency requirement did not serve a compelling state policy and, therefore, violated the DCC. During the application process, Variscite selected Brooklyn, Central New York, the Finger Lakes, the Mid-Hudson area, and Western New York as possible regions for licensure. 

Consequently, the judge ruled that New York could not issue CAURD licenses for dispensaries in those regions while the case was pending. This decision is expected to affect around 63 of the 150 CAURD licenses that the Office of Cannabis Management had planned to issue by the end of 2022. However, the ruling did not affect eleven other regions, including the Bronx, Manhattan, Queens, Staten Island, and Long Island.

Another lawsuit was recently filed by a group of larger cannabis companies, including Acreage Holdings, Columbia Care, and Curaleaf and a group of medical cannabis professionals and patients has filed a lawsuit against the state of New York, claiming that the recently passed recreational cannabis law infringes on their right to affordable and accessible medicine. The lawsuit argues that the new law, which allows for the establishment of a recreational cannabis market, will lead to shortages and increased prices for medical cannabis products. The plaintiffs contend that the state is obligated to ensure a steady supply of affordable medical cannabis products for patients, and that the new law fails to meet that obligation. 

The case highlights the challenges of balancing the needs of medical cannabis patients with the desire to establish a thriving recreational market, as more states move to legalize cannabis for both medical and recreational use.

The lawsuits come at a time when the state is still developing and finalizing its regulations for the new adult-use cannabis market. The OCM recently released its proposed rules for the industry, which include provisions aimed at promoting social equity and ensuring that small businesses have a fair shot at participating in the market.

Despite all these efforts, many stakeholders in the cannabis industry are concerned about the potential for large, out-of-state operators to dominate the market and squeeze out smaller, less capitalized local upstart businesses before they get a chance to get off the ground. They are also worried about the potential for regulatory overreach and heavy-handed enforcement.

As the state moves forward with the implementation of its new recreational cannabis market, it will need to address these and a host of other concerns in order to create a fair and equitable industry that benefits all stakeholders, from large corporations to small businesses and individual consumers. 

The lawsuits filed against the CCB and OCM are just one indication of the complex and challenging landscape that lies ahead for New York's nascent legal cannabis industry.

And, the response from across the New York cannabis industry has been mixed. Some industry leaders argue that the lawsuits are misguided and that the new laws will ultimately benefit medical cannabis patients by increasing overall demand for cannabis products and driving down prices. Others, however, acknowledge that there may be some short-term disruptions as the recreational market ramps up, and they urge the state government to take steps to ensure that medical cannabis patients are not unduly affected.

Overall, the lawsuits highlight the complex and sometimes competing interests at play in the expanding cannabis industry, as well as the challenges of balancing the needs of medical cannabis patients with the desire to establish a thriving recreational market and those interested in building an equitable and fair industry for those communities most directly impacted by the war on drugs. 

As more states legalize cannabis for both medical and recreational use, similar issues are likely to arise, and policymakers will need to not only carefully consider the impact of their decisions on all stakeholders involved, but to actually invest the time and resources in listening to each of these stakeholders and involving them in decision making process. 

Overall, the development of NY’s nascent cannbis market to a mature cannabis market is going to be a complex and dynamic process that will require careful attention to changing market conditions, industry, consumer and patient needs and regulatory requirements. 

We have to remember that we are still in the first inning of this and we will see NY’s legal cannabis industry thriving in the coming months, lawsuits and all. We’re NYers after all and we don’t let much, if anything, stand in our way. 

As Alicia Keys so soulfully sings: 

Even if it ain't all it seems

We got a pocketful of dreams 

Baby, we’re from New York

Concrete jungle where dreams are made of

There's nothin' we can't do

Now, we’re in New York

These streets will make us feel brand-new

Now, let’s hear it for New York, New York, New York

More For You

gif of actor Kevin James from King of Queens; asking "How Much Does That Cost?"
Why Is Some Weed More Expensive Than Others? Understanding Cannabis Pricing
Giphy

Unraveling Cannabis Pricing: Factors Behind the Cost of Weed


Step inside a cannabis dispensary for the first time and the experience can be overwhelming. The meticulously labeled glass jars showcase dozens of strains with names like "Wedding Cake" and "Blue Dream," while refrigerated cases display concentrates, edibles, and tinctures at wildly different price points. Unlike the days when consumers were limited to whatever their neighborhood dealer offered, today's legal market presents a dazzling array of options that might leave newcomers with both wonder and sticker shock.

Keep ReadingShow less
OCM Alleges 'Rent-a-License' Scheme, Seeks License Revocation
OCM Alleges 'Rent-a-License' Scheme, Seeks License Revocation
Photo by Jon Tyson on Unsplash

NY Revokes License in Rent-a-License Scam

Update to our coverage: Since this article was originally published, the enforcement case against Omnium Health has taken a sharp and unexpected turn. On December 8, 2025, New York’s Office of Cannabis Management abruptly withdrew the charges underpinning the license revocation, triggering leadership shakeups inside the agency and raising new questions about how the case was built and handled.

While regulators moved to step back, an administrative law judge declined to immediately dismiss the matter, leaving the door open to potential future action and lifting the recall order on roughly $30 million in Omnium products. We will continue to update this story as the situation develops.

Keep ReadingShow less
Are you paying too much attention to THC percentage? - The Bluntness

Are you paying too much attention to THC percentage? - The Bluntness

High-THC: Is % Important?

If this comes as a surprise, you’re not alone. The value of a simple number on a label receives too much credit from consumers and budtenders alike. It seems no matter how many times we think we understand cannabis, science manages to throw us off - in a good way, of course.

The question of whether percentage matter is often debated, as THC percentage alone is not a reliable indicator of overall quality or experience. Like it or not, the way cannabis interacts with the mind and body makes a simple THC measurement inaccurate to tell how high you’ll get. Potency - like many things about cannabis - is complicated.

Keep ReadingShow less
Kanye West Is Spiraling—And Our Mental Health System Is Letting It Happen - The Bluntness
Kanye West Is Spiraling—And Our Mental Health System Is Letting It Happen - The Bluntness
Photo by Axel Antas-Bergkvist on Unsplash

Kanye West Is Spiraling—And Our Mental Health System Is Letting It Happen - The Bluntness

Kanye West, aka Ye, isn’t just trending—he’s unraveling in real time. And instead of intervention, we get viral clips, condemnation, and an audience watching a man self-destruct. His latest stunt? Airing a Super Bowl ad promoting a swastika-emblazoned Yeezy shirt on his site—a move so blatantly antisemitic that even the most die-hard supporters had to step back. This act garnered significant media coverage, leading to brands cutting ties and agents dropping him. His social media account faced scrutiny and was ultimately deleted after a history of controversial postings. But here’s the problem: canceling Kanye doesn’t fix Kanye.

At this point, the question isn’t whether his actions are inexcusable (they are). The question is, what happens when one of the world’s most influential figures is also one of the most untreated cases of mental illness in pop culture history?

Keep ReadingShow less
protesters holding sign, peaceful, democracy

The Proposed Hemp Ban That Would Destroy a $28 Billion Success Story - The Bluntness

Photo by Leo_Visions on Unsplash

Hemp Ban Threatens $28B Industry

Congressional negotiators are trying to bury a hemp definition change in appropriations language, a backdoor maneuver that would treat nearly any THC in hemp-derived products as federally illegal. This is happening in real time, behind closed doors, without public hearings.

Sen. Rand Paul has pledged to hold up spending bills to stop this ban, but he's issued a stark warning: there's a "real danger" the prohibitionists win unless constituents flood Congress with calls immediately.

Keep ReadingShow less